| Hazard Information | Back Directory | [Uses]
Atrasentan sodium is an endothelin receptor antagonist with IC50 of 0.0551 nM for ETA[1]. | [References]
[1] Yuyama H, et al. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol. 2004 Sep 13;498(1-3):171-7. DOI:10.1016/j.ejphar.2004.07.003
[2] Banerjee S, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 2007 Apr 15;67(8):3818-26. DOI:10.1158/0008-5472.CAN-06-3879
[3] Weiss J, et al. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol. 2011 Oct;68(4):1093-8. DOI:10.1007/s00280-011-1715-8 |
|
|